Wolverine Trading
PRTK

Wolverine Trading’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Wolverine Trading’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-19,100
Closed -$130K – 7218
2021
Q2 		$130K Sell
19,100
-1,400
-7% -$11.3K ﹤0.01% 5274
2021
Q1 		$140K Buy
20,500
+4,700
+30% +$33.8K ﹤0.01% 5276
2020
Q4 		$98K Buy
+15,800
New +$93K ﹤0.01% 4470
2019
Q2 		– Sell
-14,300
Closed -$77K – 5312
2019
Q1 		$77K Sell
14,300
-3,800
-21% -$24.5K ﹤0.01% 4227
2018
Q4 		$94K Buy
18,100
+2,400
+15% +$18.2K ﹤0.01% 4001
2018
Q3 		$152K Sell
15,700
-8,200
-34% -$82.7K ﹤0.01% 4388
2018
Q2 		$311K Hold
23,900
– – ﹤0.01% 3725
2018
Q1 		$311K Sell
23,900
-400
-2% -$5.96K ﹤0.01% 3725
2017
Q4 		$435K Buy
24,300
+5,400
+29% +$113K ﹤0.01% 3173
2017
Q3 		$474K Buy
18,900
+5,200
+38% +$121K ﹤0.01% 2663
2017
Q2 		$349K Buy
+13,700
New +$303K ﹤0.01% 2814

Other funds holding PRTK

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
FIG
Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

Wolverine Trading's PRTK Position: Q1 2022 in Review

Wolverine Trading sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2022, closing a stake of 14,044 shares — an estimated $62K sold.

Wolverine Trading first reported a position in PRTK in Q2 2017 and held it in 10 quarters. The position peaked at $411K in Q3 2017. 100 funds tracked by Wall St. Rank hold PRTK as of Q1 2022.

  • Wolverine Trading reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • Wolverine Trading sold 14,044 Paratek Pharmaceuticals, Inc. shares in Q1 2022, an estimated $62K.
  • Wolverine Trading first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2017 and held it in 10 quarters.
  • Wolverine Trading's Paratek Pharmaceuticals, Inc. position peaked at $411K in Q3 2017.
  • 100 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2022.

Based on Wolverine Trading's 13F filing for Q1 2022, filed 16 May 2022.